within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FY02_NivolumabAndRelatlimab;
model NivolumabAndRelatlimab 
   extends Pharmacolibrary.Drugs.ATC.L.L01FY02;

  annotation(Documentation(
    info ="<html><body><p>Nivolumab and relatlimab is a fixed-dose combination immunotherapy composed of nivolumab, a PD-1 inhibitor, and relatlimab, an anti-LAG-3 antibody. The combination is indicated for the treatment of unresectable or metastatic melanoma and has received regulatory approval for use in adults and adolescents with this condition.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for adults with advanced melanoma treated in clinical trials, primarily middle-aged patients both male and female. Typical doses used in clinical trials: nivolumab 480 mg and relatlimab 160 mg, administered intravenously every 4 weeks.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end NivolumabAndRelatlimab;
